...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis
【24h】

Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis

机译:通过PCR介导的定点诱变直接检测乳腺癌和卵巢癌易感基因BRCA1中的突变

获取原文
           

摘要

The tumor suppressor genes BRCA1 and BRCA2, which confer increased susceptibility to breast and (or) ovarian cancer, were recently identified. Mutation analysis of BRCA1 has demonstrated significant allelic heterogeneity; however, some distinct mutations have been detected in unrelated individuals. The most notable is the 185delAG mutation, which occurs at an estimated frequency of ~1% in individuals of Ashkenazi Jewish descent [1] . Although consensus has not been reached regarding clinical testing for mutations in BRCA1 , a tiered strategy may be appropriate, in which direct testing for the more common mutations is one component. Specific alleles can be detected by using PCR-mediated site-directed mutagenesis (PSM), which alters the PCR products derived from either the wild-type or mutant allele to create or destroy a restriction endonuclease recognition site. Recognition sites are introduced by a base substitution in one of the primers. The alleles are then resolved by electrophoresis of the digested PCR products. We have applied this technique to the detection of four BRCA1 mutations: 185delAG, 5382insC, E1250X, and R1443X. Another mutation, 1294del40, can be resolved from the wild-type allele by high-resolution gel electrophoresis alone. The PSM technique is sensitive, does not require radioactivity, and is specific for individual mutations.
机译:最近发现了抑癌基因BRCA1和BRCA2,它们增加了对乳腺癌和(或)卵巢癌的敏感性。 BRCA1的突变分析显示出显着的等位基因异质性。但是,在无关的个体中检测到一些明显的突变。最值得注意的是185delAG突变,该突变发生在Ashkenazi犹太人后裔的个体中,估计频率约为1%[1]。尽管尚未就BRCA1突变的临床检测达成共识,但分层策略可能是合适的,其中直接检测更常见的突变是其中的一个组成部分。特定等位基因可以通过使用PCR介导的定点诱变(PSM)进行检测,该方法可以改变源自野生型或突变等位基因的PCR产物,以创建或破坏限制性核酸内切酶识别位点。通过引物之一中的碱基取代引入识别位点。然后通过消化的PCR产物的电泳分离等位基因。我们已将此技术应用于四个BRCA1突变的检测:185delAG,5382insC,E1250X和R1443X。可以单独通过高分辨率凝胶电泳从野生型等位基因中分离出另一个突变1294del40。 PSM技术灵敏,不需要放射性,并且专门针对单个突变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号